|
 
- 积分
- 429
- 威望
- 429
- 包包
- 1768
|
本帖最后由 qianqianlaile 于 2011-3-21 11:29 编辑 / r* [* c- F0 R$ T+ M1 {+ \
3 `6 ]6 }" f: v ^$ aINTRODUCTION
% `/ Q, |: l }6 {Cell therapy has tremendous potential in regenerative medicine, yet, there are concerns in ) O' b, h# K; }8 S" y$ A: i
the utility of cell therapy due to questions regarding different cell harvest and cultivation , g+ p! d+ Z9 E% g
methods (Haack-Sorensen et al., 2008; Mannello and Tonti, 2007). Bone marrow derived " N) P2 M2 s; x' ~
stem cells have been identified for a number of years, and there are a number of 6 A8 a1 j& G( ~4 A4 a. Y
ongoing clinical trials exploring the safety and efficacy of their use for a number of
. I* J p$ g$ c- P* I! u- z$ qclinical applications (Battiwalla and Hematti, 2009; Sadan et al., 2009; Satija et al.,
8 p3 E- ?7 \0 ~9 l2009). There has been an increased interest in recent years in the potential of oral-
( l2 p$ k& `0 [1 |derived stem cells for cell therapy, primarily because they can be derived from a readily ~0 J# @$ {7 o
available source, extracted teeth (Gronthos et al., 2000; Miura et al., 2003; Seo et al., ; ~* e- a& t; {6 n$ A" E
2004). These cells exhibit multipotency and regenerative capacities characteristic of
3 T- k1 j' u; ]+ i, |3 vmesenchymal stem cells (Batouli et al., 2003; Shi et al., 2005) and have the capacity to
" K/ H5 W: h% L5 F" Z x! mrepair and regenerate tooth structures in vivo (Krebsbach and Robey, 2002; Mao et al., 2006). / |; Z2 j6 i$ s- T1 m6 _+ h# O
Because oral-derived stem cells have been more recently identified, clinical
+ L! ]+ K1 L/ H i9 qprotocols are still being developed for their use. Regardless of the specific protocol
& E1 k2 @. m+ ]used, most current cell therapy approaches rely upon ex vivo cell expansion in order to
3 ^ n3 |! k5 ?) p8 @3 Jproduce sufficient cell numbers for transplantation. Though a wide variety of protocols $ V* T! \9 w d" B+ l( s, H
and culturing methods exist, one common aspect to most of them is the inclusion of $ [5 [9 T3 g" Z, e8 Q$ U9 a; ~: I
animal sera for cell expansion, in that it contains a rich source of nutrients and growth
7 u( ?1 i. Q+ K* Qfactors (Mannello and Tonti, 2007). Despite the widespread standard use of animal
2 }, F5 v& t* g! |( H+ gsera for in vitro cell culture (Freshney, 2000), there are several problems which exist
% t5 f0 D2 W+ c O6 @3 ~2 I) Mrelative to its use for clinical application.
% u4 ]; ^3 b3 ?- S4 d1 DOne of the central issues regarding limitations in using animal sera for clinical cell
$ r n# m: ]5 h' Xtherapy protocols is that its components are highly variable and, in many cases, # E( c% _) t4 O* s0 R, [& Z! @8 G. |
unknown. Though components of sera have identified, it has also been demonstrated + \3 f( h/ {; q& ?1 C; G$ o, T& F
that consistency between different lots cannot be assured (Price and Gregory, 1982). In
" M+ l$ U: r" {$ a5 Zthe context of multipotent stem cells, serum components and concentrations have / A. `( w. T* `! H* U# p' k
significant impact on cell survival and proliferative capacity, phenotype, and multipotent
- ?: s4 @( j3 [& s1 b1 l$ U9 |3 Opotential (Agata et al., 2009; Sotiropoulou et al., 2006). Additionally, for clinical use, the 2 K+ [- K) k7 B8 Q5 U
inclusion of xenogeneic serum for cell expansion carries immunological risks associated
; e& G; k' I3 Z0 Jwith the immunogenicity of serum proteins and the potential of transmission of prion
; A9 c/ h% z! \# D8 bdiseases and zoonoses (Shahdadfar et al., 2005). These concerns have led to efforts 7 W2 D' Z3 i; @2 U; a' Q1 U
aimed at incorporating FBS alternatives in cell expansion protocols, including the use of ) A" J, g0 @- m. ~% t
autologous and allogeneic sera, and the proprietary manufacturing of serum-free media
! A9 m3 t! z* d u& p' p; N, cformulations by different companies (Nakamura et al., 2008). Even with these approaches,
0 |' |* B, t, I% E5 C there are limitations in the availability of both autologous and allogeneic
$ D. Z h3 @9 P) G; hsera and companies do not freely disclose their proprietary “serum-free” media 3 x P$ P/ M: u0 W: c. \
components. These factors not only prohibit clinical translation, but also limit
& v5 R7 N- ]" t P7 n$ n3 G3 Mwidespread use and study of more basic fundamental questions regarding specific
% J/ y1 P+ S5 {, Wmechanisms involved in the modulation of these media on cell function. As such, there * }- H; \+ w; k# @6 @( X
exists a need for the development of chemically-defined media which can propagate the
0 y0 S9 T) u# \6 D$ [* acultivation of stem cells without adversely affecting cell function and phenotype 0 s/ ^: L2 R8 l3 e6 u
(Mannello and Tonti, 2007).! {' e4 B" Y: J; z9 p* V3 j
In this study, we aimed to develop a serum-free media (K-M) for the expansion o5 l* ~# n$ U+ S' s$ f; S8 }+ i3 k. S
dental-derived stem cells, including stem cells-derived from exfoliated deciduous (baby)$ o6 Z |6 o y+ g Q+ ^, B
teeth (SHEDs) and periodontal ligament stems cells (PDLSCs). Cell expansion in this
% \( o/ q/ @5 U5 T( e, P' N# _) imedia was compared to standard FBS containing media used to culture these cells, 6 d9 I5 V' G. m& J, D9 x
as well as three other serum-free media formulations (two of which are commercially available) , c. T$ K5 O$ i) I$ D
used for culture of mesenchymal stem cells. Additionally, through
g# R( Y) N( z8 J7 s; }2 U4 I( wdifferentiation assays and microarray analyses, multipotency and differential gene : e9 l2 s$ V* `( Q; e8 @# G
expression of 84 stem cell associated genes was examined between cells cultured in K-/ k- O* j5 X, w5 r
M vs. those cultured in FBS- containing media. |
|
发表于 2011-3-20 08:21
& G, P. B& V, e
，脑子里也没有独家生产这个概念
，所以没理解。) w* Z; ?: R3 ^) x/ h2 o